KenSci Raises $22 Million in Series B Funding to Fuel Growth

The round was led by Polaris Partners with participation from UL Ventures and all existing investors.

SEATTLE /PRNewswire/ -- KenSci, a Machine Learning and Artificial Intelligence powered, risk prediction platform for healthcare, announced today that it has closed $22 million in Series B funding. The funding round was led by Polaris Partners and witnessed strong participation from all existing investors including Ignition Partners, Osage University Partners, and Mindset Ventures. UL Ventures joined the round as a strategic investor, offering global reach and compliance expertise. The investment will further accelerate KenSci's product roadmap and global expansion.

Commenting on the fundraising round, Samir Manjure, Co-Founder and CEO of KenSci,  said, "In the last two years, we've singularly invested ourselves in building a platform that simplifies the way health systems look at their data and gain actionable, predictive insights to save lives and costs. With this round of funding, we're excited to take these capabilities to a global stage with partners who complement our capabilities and are committed to helping us drive this transformation across the care continuum."

"KenSci has rapidly scaled to become one of the leading names in healthcare," said Brian Chee, managing partner at Polaris Partners. "What KenSci has accomplished is extremely exciting and we're thrilled to partner with them as they bring healthcare professionals both clinical and operational insights."

Founded by Prof. Ankur Teredesai, from the University of Washington Tacoma, and Samir Manjure, a longtime Microsoft executive, KenSci's risk prediction platform has helped some of the leading health systems across the globe align better to quadruple aim and improve the quality of care they provide at lower costs.

KenSci's risk prediction platform is built on Azure ML, SQL and provides insights using Power BI. The platform ingests data from health sources, such as EMR, Claims, Billings, Pharmacy, Wearable, and Psychosocial data, to identify patterns that help uncover opportunities to save costs and lives. With this round of funding, KenSci aims to align closely with health systems helping them overcome challenges in utilization, variation, and hospital operations with data-led predictive insights.

A three-year-old organization, this round brings KenSci's total funding to $30.5 million. In 2018, KenSci was recognized as the winner of the Microsoft Health Innovation Awards for the best use of AI and ML.

 


KenSci was incubated at University of Washington's Center for Data Science at UW Tacoma and designed on the cloud with help from Microsoft's Azure4Research grant program. KenSci is headquartered in Seattle, with offices in Singaporeand Hyderabad. For more information, visit www.kensci.com.

Press Contacts:

Abhilash Kumar | Director of Marketing
abhi@kensci.com

+91 98458 72451

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

KenSci

KenSci's machine learning powered risk prediction platform helps healthcare providers and payers intervene early by identifying clinical, financial and operational risk to save costs and lives. KenSci's platform is engineered to ingest, transform and integrate healthcare data across clinical, claims, and patient generated sources. A library of pre-built models and modular solutions allows KenSci's ML platform to integrate into existing workflows. With Explainable AI models for healthcare, KenSci is making risk based prediction more efficient and accountable.